Evolus, Inc. (NASDAQ:EOLS) Stock Has Average Target Price of $15.00

Key Points

• Analyst sentiment is moderately positive: Four of six analysts rate Evolus a buy, one says hold, and one says sell; the average 12-month price target is $15.
• Evolus shares were at $6.80, well below the consensus target, and had a 52-week range of $3.86 to $9.31. BTIG recently raised its target from $13 to $15 and reiterated a buy rating.
• Institutional investors own 90.69% of the stock. Company insider David Moatazedi sold 105,108 shares at an average price of $9.04, reducing his holdings by 17.38%.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.00.

Several brokerages have commented on EOLS. BTIG Research raised their target price on shares of Evolus from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday. HC Wainwright restated a "buy" rating and issued a $13.00 price target on shares of Evolus in a research report on Tuesday, August 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Evolus in a research report on Friday, September 11th. Finally, Wall Street Zen raised shares of Evolus from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th.

Insider Activity

In related news, insider David Moatazedi sold 105,108 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the transaction, the insider directly owned 499,592 shares of the company's stock, valued at approximately $4,516,311.68. The trade was a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC acquired a new stake in shares of Evolus during the 2nd quarter valued at about $38,878,026. BlackRock Inc. acquired a new stake in Evolus in the second quarter valued at approximately $33,595,000. Braidwell LP lifted its stake in Evolus by 1.6% in the second quarter. Braidwell LP now owns 3,155,209 shares of the company's stock valued at $21,897,000 after acquiring an additional 50,000 shares during the last quarter. Pinnacle Associates Ltd. grew its position in Evolus by 5.6% in the third quarter. Pinnacle Associates Ltd. now owns 1,570,061 shares of the company's stock worth $12,560,000 after acquiring an additional 82,797 shares in the last quarter. Finally, Rice Hall James & Associates LLC bought a new stake in Evolus in the second quarter worth approximately $8,952,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Stock Performance

Shares of NASDAQ:EOLS remained flat at $6.80 during midday trading on Friday. The company had a trading volume of 1,521,612 shares, compared to its average volume of 709,793. The company has a fifty day simple moving average of $7.81 and a two-hundred day simple moving average of $6.31. The company has a market capitalization of $449.14 million, a price-to-earnings ratio of -14.47 and a beta of 1.38. Evolus has a fifty-two week low of $3.86 and a fifty-two week high of $9.31.

Evolus Company Profile

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company's business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus' primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.